This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and
pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who
have received commercially supplied belimumab within the 4 months prior to and/or during
pregnancy. The registry will also evaluate outcomes of infants born to mothers who were
exposed to belimumab within the 4 months prior to and/or during pregnancy. This registry will
add to the current clinical experience with belimumab and will complement reproductive data
from animal toxicology studies. It will also assist clinicians in weighing the potential
risks against the benefits of treatment for individual patients with SLE. GlaxoSmithKline
(GSK) will sponsor the Belimumab Pregnancy Registry in countries where it holds Marketing
Authorization.